Literature DB >> 16299322

Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.

Zhiming Huo1, Ruchi Sinha, Edel A McNeela, Ray Borrow, Rafaela Giemza, Catherine Cosgrove, Paul T Heath, Kingston H G Mills, Rino Rappuoli, George E Griffin, David J M Lewis.   

Abstract

Thirty-six healthy volunteers received either a single intramuscular injection of Neisseria meningitidis serogroup C polysaccharide (MCP)-CRM197 conjugate vaccine in alum or two nasal insufflations 28 days apart of the same vaccine powder, without alum, mixed with chitosan. Nasal immunization was well tolerated, with fewer symptoms reported than after intramuscular injection. The geometric mean concentrations of MCP-specific immunoglobulin G (IgG) after one nasal immunization were 3.25 microg/ml in naïve subjects and 14.4 microg/ml in subjects previously immunized parenterally, compared with 4.30 microg/ml in naïve subjects immunized intramuscularly. The geometric mean titer of serum bactericidal antibody (SBA) rose 24-fold after two nasal immunizations in naïve subjects and was comparable to parenteral immunization (1,080 versus 1,625). All subjects achieved SBA titers associated with protection after two nasal immunizations: even those with titers of <8 at entry. A single nasal immunization boosted the SBA titer to > or =128 in 96% of previously immunized subjects, and two immunizations achieved this level in 92% of naive subjects. MCP-specific IgG levels were approximately 70% IgG2 and approximately 20% IgG1 after nasal or intramuscular immunization. Increases in CRM197-specific IgG and diphtheria toxin-neutralizing activity were observed after nasal or intramuscular immunization, with balanced IgG1/IgG2 and higher IgG4. Significant MCP-specific secretory IgA was detected in nasal wash only after nasal immunization and predominantly on the immunized side. Simple nasal insufflation of existing MCP-CRM197 conjugate vaccines in chitosan offers an inexpensive but effective needle-free prime and boost against serogroup C N. meningitidis and diphtheria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299322      PMCID: PMC1307064          DOI: 10.1128/IAI.73.12.8256-8265.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.

Authors:  E A McNeela; D O'Connor; I Jabbal-Gill; L Illum; S S Davis; M Pizza; S Peppoloni; R Rappuoli; K H Mills
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

2.  A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers.

Authors:  A K H Berstad; J Holst; L O Frøholm; I L Haugen; E Wedege; F Oftung; B Haneberg
Journal:  J Med Microbiol       Date:  2000-02       Impact factor: 2.472

3.  Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.

Authors:  Rohit K Katial; Brenda L Brandt; Ellen E Moran; Stephen Marks; Victor Agnello; Wendell D Zollinger
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  Limitations of Pneumovax as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay.

Authors:  Z M Huo; J Miles; P G Riches; T Harris
Journal:  Ann Clin Biochem       Date:  2002-07       Impact factor: 2.057

5.  Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.

Authors:  Kingston H G Mills; Catherine Cosgrove; Edel A McNeela; Amy Sexton; Rafaela Giemza; Inderjit Jabbal-Gill; Anne Church; Wu Lin; Lisbeth Illum; Audino Podda; Rino Rappuoli; Mariagrazia Pizza; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

Review 6.  Impact of meningococcal C conjugate vaccine in the UK.

Authors:  P Balmer; R Borrow; E Miller
Journal:  J Med Microbiol       Date:  2002-09       Impact factor: 2.472

7.  Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults.

Authors:  David Goldblatt; Ray Borrow; Elizabeth Miller
Journal:  J Infect Dis       Date:  2002-01-10       Impact factor: 5.226

8.  Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine.

Authors:  A K Berstad; F Oftung; G E Korsvold; I L Haugen; L O Froholm; J Holst; B Haneberg
Journal:  Vaccine       Date:  2000-05-08       Impact factor: 3.641

9.  Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Authors:  L F Fries; A D Montemarano; C P Mallett; D N Taylor; T L Hale; G H Lowell
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

10.  Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.

Authors:  M Larbig; E Mansouri; J Freihorst; B Tümmler; G Köhler; H Domdey; B Knapp; K D Hungerer; E Hundt; J Gabelsberger; B U von Specht
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

View more
  14 in total

1.  Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses.

Authors:  Pavan Muttil; Brian Pulliam; Lucila Garcia-Contreras; John Kevin Fallon; Chenchen Wang; Anthony James Hickey; David A Edwards
Journal:  AAPS J       Date:  2010-09-28       Impact factor: 4.009

2.  Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine.

Authors:  Helen Findlow; Jo Southern; Lesley Mabey; Paul Balmer; Robert S Heyderman; Cressida Auckland; Rhonwen Morris; Elizabeth Miller; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2006-04

3.  Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

Authors:  Samer S El-Kamary; Marcela F Pasetti; Paul M Mendelman; Sharon E Frey; David I Bernstein; John J Treanor; Jennifer Ferreira; Wilbur H Chen; Richard Sublett; Charles Richardson; Robert F Bargatze; Marcelo B Sztein; Carol O Tacket
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

4.  Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection.

Authors:  Yong Xie; Nan-Jin Zhou; Yan-Feng Gong; Xiao-Jiang Zhou; Jiang Chen; Si-Juan Hu; Nong-Hua Lu; Xiao-Hua Hou
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

Review 5.  Intranasal immunization with dry powder vaccines.

Authors:  Tania F Bahamondez-Canas; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2017-11-06       Impact factor: 5.571

6.  Evaluation of mucosal adjuvants and immunization routes for the induction of systemic and mucosal humoral immune responses in macaques.

Authors:  Ronald S Veazey; Asna Siddiqui; Katja Klein; Viviana Buffa; Lucia Fischetti; Lara Doyle-Meyers; Deborah F King; John S Tregoning; Robin J Shattock
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.

Authors:  S D Klas; C R Petrie; S J Warwood; M S Williams; C L Olds; J P Stenz; A M Cheff; M Hinchcliffe; C Richardson; S Wimer
Journal:  Vaccine       Date:  2008-08-12       Impact factor: 3.641

8.  Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.

Authors:  Sachin G Thakkar; Zachary N Warnken; Riyad F Alzhrani; Solange A Valdes; Abdulaziz M Aldayel; Haiyue Xu; Robert O Williams; Zhengrong Cui
Journal:  J Control Release       Date:  2018-10-16       Impact factor: 9.776

9.  Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.

Authors:  Catherine A Cosgrove; Charles J Lacey; Alethea V Cope; Angela Bartolf; Georgina Morris; Celine Yan; Susan Baden; Tom Cole; Darrick Carter; Elizabeth Brodnicki; Xiaoying Shen; Sarah Joseph; Stephen C DeRosa; Lili Peng; Xuesong Yu; Guido Ferrari; Mike Seaman; David C Montefiori; Nicole Frahm; Georgia D Tomaras; Wolfgang Stöhr; Sheena McCormack; Robin J Shattock
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

Review 10.  Chitosans for delivery of nucleic acids.

Authors:  Michael D Buschmann; Abderrazzak Merzouki; Marc Lavertu; Marc Thibault; Myriam Jean; Vincent Darras
Journal:  Adv Drug Deliv Rev       Date:  2013-07-18       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.